Skip to main content
OpenTrials

Clinical trial condition

Triple Negative Breast Neoplasms

Explore clinical trials studying Triple Negative Breast Neoplasms. Study availability and eligibility vary by location and protocol.

819 public trials 296 recruiting studies
Refine in advanced search Browse all conditions

Triple Negative Breast Neoplasms trial results

Completed

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

NCT01964924

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor Negative, +11 more
Locations
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
View Trial Details
Completed

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

NCT02307240

Conditions
Breast Diseases, Breast Neoplasms, High-grade Serous Ovarian Cancer, +8 more
Locations
  • UCSF School of Medicine San Francisco, California, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Emotions Immunology and Breast Cancer

NCT03609671

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +8 more
Locations
  • Houston Methodist Hospital Cancer Center Houston, Texas, United States
  • Houston Methodist Hospital Houston, Texas, United States
View Trial Details
Completed

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

NCT02309177

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +18 more
Locations
  • UC Davis Cancer Center Sacramento, California, United States
  • University of California Los Angeles Santa Monica, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
  • H. Lee Moffitt Cancer Center and Research Institute University of South Florida Tampa, Florida, United States
View all 15 locations
View Trial Details
Completed

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

NCT01997333

Conditions
Breast Diseases, Breast Neoplasms, Metastatic gpNMB Over-expressing Triple Negative Breast Cancer, +5 more
Locations
  • Alabama Oncology Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of South Alabama Cancer Research Insititute Mobile, Alabama, United States
  • Arizona Cancer Research Alliance Glendale, Arizona, United States
View all 140 locations
View Trial Details
Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

NCT01881230

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +15 more
Locations
  • Ironwood Cancer and Research Center Chandler, Arizona, United States
  • Arizona Center for Cancer Care Glendale, Arizona, United States
  • Arizona Cancer Research Alliance Scottsdale, Arizona, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
View all 140 locations
View Trial Details
Completed

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)

NCT02580448

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +12 more
Locations
  • Wallace Tumor Institute- University of Alabama Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • University of Colorado Aurora, Colorado, United States
  • Rocky Mountain Cancer Centers Lakewood, Colorado, United States
View all 36 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

NCT00733408

Conditions
Breast Diseases, Breast Neoplasms, Estrogen Receptor-negative Breast Cancer, +10 more
Locations
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Yuma Cancer Center Yuma, Arizona, United States
View all 17 locations
View Trial Details

Related conditions